Compounds and compositions for intracellular delivery of agents
View Patent ↗The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanoparticle compositions further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
1. A compound being
or a salt or isomer thereof.
2. The compound of claim 1 , wherein the salt is a pharmaceutically acceptable salt.
3. A nanoparticle composition comprising a lipid component comprising the compound of claim 1 .
4. The nanoparticle composition of claim 3 , wherein the lipid component further comprises a phospholipid.
5. The nanoparticle composition of claim 4 , wherein the phospholipid is selected from the group consisting of
1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),
1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),
1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),
1,2-dilinolenoyl-sn-glycero-3-phosphocholine,
1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),
1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,
1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,
1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG),
sphingomyelin, and
mixtures thereof.
6. The nanoparticle composition of claim 5 , wherein the phospholipid is DSPC or DOPE.
7. The nanoparticle composition of claim 4 , wherein the lipid component further comprises a structural lipid.
8. The nanoparticle composition of claim 7 , wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.
9. The nanoparticle composition of claim 8 , wherein the structural lipid is cholesterol.
10. The nanoparticle composition of claim 7 , wherein the lipid component further comprises a PEG lipid.
11. The nanoparticle composition of claim 10 , wherein the PEG lipid is selected from the group consisting of a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.
12. The nanoparticle composition of claim 10 , wherein the lipid component comprises about 30 mol % to about 60 mol % said compound, about 0 mol % to about 30 mol % phospholipid, about 18.5 mol % to about 48.5 mol % structural lipid, and about 0 mol % to about 10 mol % PEG lipid.
13. The nanoparticle composition of claim 10 , wherein the lipid component comprises about 35 mol % to about 55 mol % said compound, about 5 mol % to about 25 mol % phospholipid, about 30 mol % to about 40 mol % structural lipid, and about 0 mol % to about 10 mol % PEG lipid.
14. The nanoparticle composition of claim 10 , wherein the lipid component comprises about 50 mol % said compound, about 10 mol % phospholipid, about 38.5 mol % structural lipid, and about 1.5 mol % PEG lipid.
15. The nanoparticle composition of claim 10 , further comprising a therapeutic and/or prophylactic agent.
16. The nanoparticle composition of claim 12 , further comprising a therapeutic and/or prophylactic agent.
17. The nanoparticle composition of claim 13 , further comprising a therapeutic and/or prophylactic agent.
18. The nanoparticle composition of claim 15 , wherein the therapeutic and/or prophylactic agent is a nucleic acid.
19. The nanoparticle composition of claim 15 , wherein the therapeutic and/or prophylactic agent is a ribonucleic acid (RNA).
20. The nanoparticle composition of claim 19 , wherein the RNA is selected from the group consisting of a small interfering RNA (siRNA), an asymmetrical interfering RNA (aiRNA), a microRNA (miRNA), a Dicer-substrate RNA (dsRNA), a small hairpin RNA (shRNA), a messenger RNA (mRNA), and mixtures thereof.
21. The nanoparticle composition of claim 19 , wherein the RNA is mRNA.
22. The nanoparticle composition of claim 21 , wherein the mRNA includes one or more of a stem loop, a chain terminating nucleoside, a polyA sequence, a polyadenylation signal, and/or a 5′ cap structure.
23. The nanoparticle composition of claim 21 , wherein the encapsulation efficiency of the therapeutic and/or prophylactic agent is at least 80% or at least 90%.
24. The nanoparticle composition of claim 21 , wherein the wt/wt ratio of the lipid component to the mRNA is from about 10:1 to about 60:1.
25. The nanoparticle composition of claim 21 , wherein the wt/wt ratio of the lipid component to the mRNA is about 20:1.
26. The nanoparticle composition of claim 21 , wherein the N:P ratio is from about 5:1 to about 8:1.
27. A pharmaceutical composition comprising the nanoparticle composition of claim 21 and a pharmaceutically acceptable carrier.
28. A method of delivering a therapeutic and/or prophylactic agent to a mammalian cell, the method comprising administering to a subject the nanoparticle composition of claim 15 , said administering comprising contacting the cell with the nanoparticle composition, whereby the therapeutic and/or prophylactic agent is delivered to the cell.
29. A method of producing a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the nanoparticle composition of claim 21 , wherein the mRNA encodes the polypeptide of interest, whereby the mRNA is capable of being translated in the cell to produce the polypeptide of interest.
30. A method of treating a disease or disorder in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of the nanoparticle composition of any claim 15 .